Rockwell Medical Inc
NASDAQ:RMTI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.23
4.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Rockwell Medical Inc
Rockwell Medical Inc
Research & Development
Rockwell Medical Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rockwell Medical Inc
NASDAQ:RMTI
|
Research & Development
-$186k
|
CAGR 3-Years
71%
|
CAGR 5-Years
52%
|
CAGR 10-Years
34%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Research & Development
-$59.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-2%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Research & Development
-$88.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-18%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Research & Development
-$351.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-21%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Research & Development
-$149.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-27%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Research & Development
-$83.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-9%
|
|
Rockwell Medical Inc
Glance View
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 300 full-time employees. The firm is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. The company is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The firm has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.
See Also
What is Rockwell Medical Inc's Research & Development?
Research & Development
-186k
USD
Based on the financial report for Sep 30, 2024, Rockwell Medical Inc's Research & Development amounts to -186k USD.
What is Rockwell Medical Inc's Research & Development growth rate?
Research & Development CAGR 10Y
34%
Over the last year, the Research & Development growth was 83%. The average annual Research & Development growth rates for Rockwell Medical Inc have been 71% over the past three years , 52% over the past five years , and 34% over the past ten years .
You don't have any saved screeners yet
